Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

Summary

This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors

Interventions

• LT-010391 · DRUG

  LT-010391 tablets, oral, once daily

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Participants with histologically or cytologically confirmed advanced solid tumors harboring a KRAS G12D mutation;
* Failed standard therapy, intolerant to standard therapy, or no standard therapy is available;
* ECOG Performance Status of 0 or 1;
* Adequate organ function

Exclusion Criteria:

* History of ≥2 primary malignancies within 5 years prior to signing informed consent, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or other malignancies considered cured;
* Primary central nervous system (CNS) tumors
* leptomeningeal metastases, brainstem metastases, or spinal cord compression confirmed by imaging (regardless of symptoms) Other inclusion/exclusion criteria may apply.

Sites (1)

• Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China